Skincare startup Numour in talks to raise $3.1 million

What did Sharp Ventures do with Naturis and Numour?

Sharrp Ventures, the investment office of the Harsh Mariwala family (the founder of Marico, a consumer goods company), led a ₹100 crore funding round in July for Naturis Cosmetics, a contract manufacturer that makes products for brands like Nykaa and Plum. It is now reportedly leading a ₹30 crore round for Numour, a skincare and beauty-device brand. The two deals span both ends of the beauty supply chain.

Why would a family office back a 2025 startup instead of just the proven?

The factory is the safe bet: Naturis has grown revenue 40% to ₹154 crore and stayed profitable, while Numour is a brand founded in 2025 with no track record. But Sharrp already holds a 6.19% stake in Naturis. Backing Numour adds consumer exposure.

Why would an investor back both the factory and the brands it serves?

Sharrp already owns a 6.19% stake in Naturis, the contract manufacturer that makes products for brands like Nykaa and Plum. Backing Numour, a brand that sells through those same marketplaces, gives Sharrp exposure to the consumer side of the same supply chain. The two bets are complementary: the factory profits whether or not any single brand wins, while a successful brand can scale quickly on the factory's capacity. Our read: Sharrp is hedging by owning both ends of beauty's value chain.

Whose products would a beauty-device brand rely on to make them, though?

Numour sells serums and sunscreen as well as LED-equipped jars and sonic massagers, but the coverage of the proposed round does not say who manufactures those products. Naturis, Sharrp's existing investment, is a contract manufacturer that makes skincare, haircare and makeup for more than 50 brands, including Nykaa, Plum and Kay Beauty. If Numour outsources to Naturis, Sharrp's two bets would be directly linked, with the factory gaining a captive customer and the brand gaining access to proven production. That linkage is not confirmed in the available reporting. Our read: the round's logic is stronger if Numour is already a Naturis client, since the factory bet then de-risks the brand bet in the same supply chain.

What happens if the brand outgrows the investor's own factory?

Naturis, the factory Sharrp already backs, makes skincare, haircare and makeup for more than 50 brands, including Nykaa, Plum and Kay Beauty. If Numour outgrows what Naturis can produce, it can shift some volume to other manufacturers, as contract manufacturers typically work with many clients. That would weaken the direct link between Sharrp's two bets, but the factory still profits from the broader D2C boom regardless of Numour's fate. Our read: owning the factory caps the downside if Numour stalls, but does not cap Numour's upside if it scales beyond Naturis's capacity.

Who ends up manufacturing the devices if the factory only does cosmetics?

Naturis manufactures skincare, haircare, makeup and personal-care products, but the available reporting does not say whether it makes consumer beauty devices. Numour sells LED-equipped jars, sonic massagers and facial devices alongside serums and sunscreen, and no evidence names a device manufacturer for those products. If Naturis cannot produce them, Numour would need a separate electronics or device supplier, splitting its supply chain between Sharrp's factory and an unaffiliated maker. Our read: the brand's device line sits outside the investor's factory hedge, leaving that half of the portfolio without a captive manufacturer.

Why would a device maker choose beauty products as its first bet?

Numour is a young brand with no manufacturing base of its own; it sells serums, sunscreens and devices through marketplaces, quick commerce and Broadway stores. Its pitch is that pairing ingredient-led formulas with LED and sonic technology sets it apart from brands that sell only topical products. That positioning matters because the D2C beauty market is crowded, so discovery and repeat purchases decide which brands survive. Our read: the device angle is what justifies an early-stage valuation in a market where most skincare launches look alike.

If Sharrp already bet on the factory, why would it need the brand's devices at all?

Sharrp's bet on Naturis covers cosmetics manufacturing, but Numour's devices sit outside that factory's line. Naturis makes skincare, haircare, makeup and personal care, with no evidence it produces LED jars, sonic massagers or facial devices. So the device half of Numour's portfolio needs a separate supplier, one Sharrp does not own. The brand is what ties the two bets together: without a consumer-facing device maker, Sharrp's factory hedge does not extend to the technology side. Our read: the brand purchase is how Sharrp gets exposure to device-led beauty without owning a hardware factory.

What decides whether bet on beauty brands like Numour pays off?

India's direct-to-consumer (D2C) market is projected to grow from $65 billion in 2026 to $310 billion by 2031, but that growth will spread across many brands. The winners will be those that secure repeat purchases and distribution, as Numour is trying to do across Amazon, Nykaa, Blinkit and Broadway stores. Our read: the real test is whether Numour's device-led products drive enough repeat sales to justify the round.

What's the shift if Sharp just buys into two beauty companies?

The shift is that beauty investors are no longer concentrating only on flashy consumer brands. D2C labels scale fast because they don't own factories, so someone must own those factories. Sharrp's July ₹100 crore bet on contract manufacturer Naturis, followed by talks to fund consumer brand Numour, shows money flowing to both ends of the supply chain, a sign the sector is maturing.

Why do beauty-device products matter for repeat purchases?

Numour pairs skincare with LED-equipped jars, sonic massagers and facial devices, betting that technology-led products drive repeat sales better than creams alone. The brand's pitch is that delivery systems carry active ingredients past the skin's surface barrier, a claim it states rather than clinically proves. Our read: devices create a reason for customers to return and reorder, which is the repeat-purchase engine that decides whether a young D2C brand survives a crowded market where discovery, retention and distribution shape growth.

What does a single investor owning both the factory and the brand change for the startup?

Sharrp Ventures already holds a 6.19% stake in Naturis Cosmetics, the contract manufacturer that makes products for beauty brands, after leading a ₹100 crore round in July. If it also funds Numour, Sharrp covers the supply chain from production to consumer. For Numour, this means its investor has a direct stake in the factory that could make its products, creating an incentive for Naturis to prioritise Numour's orders. Our read: the relationship gives Numour a manufacturing advantage that rivals without such an investor would struggle to match.

What does the family office get from owning both ends of the same market?

Sharrp Ventures has invested in roughly 34 companies across early and growth stages, including consumer brands like Mamaearth and Nykaa, and now holds a 6.19% stake in contract manufacturer Naturis Cosmetics while courting brand Numour. Owning both ends gives Sharrp pricing power and deal flow: it sees manufacturing costs on one side and consumer demand on the other, which strengthens its negotiating position in future beauty investments. Our read: Sharrp is building a platform, not making isolated bets, positioning itself as the go-to capital source for the sector.

How does a family office make money from two sides of one market?

Sharrp Ventures, the Harsh Mariwala family's investment office, has backed roughly 34 companies including Mamaearth, Nykaa and MCaffeine, and now holds stakes in contract manufacturer Naturis Cosmetics and, if the deal closes, consumer brand Numour. The family office earns when portfolio companies grow in value, and its array of consumer investments lets it compare brand performance against manufacturing demand. Our read: Sharrp monetises by building a reputation as a go-to beauty investor, which attracts more deal flow and better pricing on future rounds, rather than by extracting margins from its own portfolio.

What happens if the Numour deal falls through for the investor?

The Numour round has not been finalised and the company has not confirmed the talks. If it falls through, Sharrp Ventures still holds its 6.19% stake in Naturis Cosmetics, the contract manufacturer with ₹154 crore revenue and ₹12 crore profit in FY25. Sharrp has invested in roughly 34 companies across consumer brands like Mamaearth and Nykaa, so a single missed deal would not threaten its platform. Our read: Sharrp's manufacturing bet carries the downside protection, while Numour is the optional upside that can be walked away from.

Can Sharrp push Numour's products through Naturis without conflict?

Sharrp holds a 6.19% stake in Naturis, which manufactures for 50+ brands including Nykaa, Plum and Pilgrim, but Naturis serves many competing clients. The contract manufacturer's model depends on serving all brands equally, so Sharrp cannot openly favour Numour without risking its other clients. Our read: any manufacturing advantage would be informal and limited, not a structural edge.

Why does a family office place two bets instead of one on beauty?

Sharrp Ventures, the investment office of the Harsh Mariwala family, already backed Naturis, a profitable contract manufacturer with ₹154 crore revenue, and now courts Numour, a 2025 startup with no track record. The two bets carry different risks: Naturis offers steady returns from manufacturing, while Numour offers upside from a consumer brand in a market projected to grow from $65 billion to $310 billion by 2031. Our read: one investment offsets the other, letting Sharrp tap the sector's growth without betting everything on a single unproven brand.

Why is Sharp betting on both factory and brand?

Investor money in beauty used to go to consumer-facing brands, since they are asset-light and scale fast without owning factories. But manufacturers grow with those brands, so backing both spreads risk. Naturis, profitable since 2011, is the safer bet; Numour, founded in 2025, is the consumer bet. Funding both hedges the investment.

Why would a family office back a startup that sells LED facial devices?

Sharrp Ventures is the investment office of the Harsh Mariwala family, whose portfolio already spans major consumer brands like Mamaearth and Nykaa. Numour's product range mixes familiar skincare categories like sunscreens and serums with gadget-style items such as LED-equipped jars and sonic massagers. The device-led angle is meant to set the brand apart from companies selling only topical formulas, tapping the broader trend of pairing ingredient-led skincare with technology. Our read: the bet is that device attachment drives repeat purchases, not that the hardware itself becomes a standalone business.

Why would a family office back a hardware-heavy brand it can't easily scale?

Sharrp already owns 6.19% of Naturis, the contract manufacturer that makes products for brands like Nykaa and Plum. Backing Numour alongside Naturis lets Sharrp capture margin at both ends: the factory earns from making the goods, and the brand earns from selling them. The device aspect also gives Numour a differentiation angle in a crowded market, though the company has not disclosed clinical evidence for its LED and sonic claims. Our read: Sharrp is betting the two investments reinforce each other, not that the hardware alone justifies the round.

What happens to the factory's other clients if it starts favouring Numour?

Naturis already serves 50-plus brands including Nykaa, Plum, Pilgrim and Bare Anatomy, and Sharrp owns 6.19% of it, so any extra production for Numour is one allocation within a large book of business, not a shift of the whole plant. The evidence does not say how Naturis will prioritise orders or whether Numour gets preferential rates or timelines. Our read: the factory's existing clients anchor its revenue, so Sharrp will not risk those relationships for a startup that has yet to prove repeat sales.

Why would Sharrp, a family office, back two beauty bets at once?

Sharrp Ventures is the investment office of the Harsh Mariwala family, and it already holds a 6.19% stake in Naturis Cosmetics, a contract manufacturer that serves 50-plus brands including Nykaa and Plum. Backing Numour alongside Naturis would let Sharrp capture margin at both ends: the factory earns from making goods, and the brand earns from selling them. Our read: the two investments are meant to reinforce each other, with Naturis positioned to manufacture for Numour while Sharrp hedges across both manufacturing and consumer exposure.

What happens to the factory's other clients if it keeps making for its own brand?

Naturis serves 50-plus brands including Nykaa, Plum and Pilgrim, so Numour would be one allocation within a large book of business, not a shift of the whole plant. The evidence does not say whether Numour gets preferential rates or timelines, and Naturis's existing clients anchor its revenue. Our read: Sharrp will not risk those relationships for a brand with no proven repeat sales, so the factory keeps its neutrality to protect the margin that made it worth funding.

Can a 2025 brand with no numbers even be valued for a deal like this?

No public revenue figures exist for Numour, so the valuation Sharrp negotiates would rest on comparables and the founder's roadmap rather than financials. Sharrp knows this pattern well: its own bet on Naturis was priced at ₹364 crore post-money against ₹154 crore in revenue and ₹12 crore profit. Numour's deal is different in kind, a bet on the D2C market growing from $65 billion in 2026 to $310 billion by 2031, not on what the brand has already sold. Our read: the term sheet will be built on milestones tied to distribution and repeat sales, not on a worth that exists today.

What does the money from this round actually buy?

Numour is a 2025 startup with no public revenue or profitability figures, so the $3.1 million round is early-stage capital. The brand sells through its own site, Amazon, Nykaa, Flipkart, Myntra, Blinkit and Broadway stores, which suggests the funds will go toward securing distribution and driving discovery in a crowded market. The stated plan is to pair ingredient-led formulas with delivery technologies like LED and sonic devices, which requires product development investment. The company has not detailed how it will spend the proceeds beyond these growth priorities.